Prevalence of antipsychotic polypharmacy in patients with schizophrenia and other psychotic disorders in the MENAT and EMRO countries: a systematic review and meta-analysis (opens in new tab)

Antipsychotic monotherapy is considered the standard for schizophrenia treatment. However, many patients with schizophrenia and other psychotic disorders receive antipsychotic polypharmacy (APP). This can be associated with increased adverse effects, drug interactions, and treatment costs. This review aims to synthesize evidence on the prevalence of APP in the Middle East, North Africa, Turkey, and the Eastern Mediterranean (MENAT/EMRO) countries. Eight databases were systematically searched ...